Analytical Data
-
基因名
PLK1
- Application
-
别名
PLK1；PLK；Serine/threonine-Protein kinase PLK1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P53350
-
表达区间
1-603aa
-
氨基酸序列
MSAAVTAGKL ARAPADPGKA GVPGVAAPGA PAAAPPAKEI PEVLVDPRSR RRYVRGRFLG KGGFAKCFEI SDADTKEVFA GKIVPKSLLL KPHQREKMSM EISIHRSLAH QHVVGFHGFF EDNDFVFVVL ELCRRRSLLE LHKRRKALTE PEARYYLRQI VLGCQYLHRN RVIHRDLKLG NLFLNEDLEV KIGDFGLATK VEYDGERKKT LCGTPNYIAP EVLSKKGHSF EVDVWSIGCI MYTLLVGKPP FETSCLKETY LRIKKNEYSI PKHINPVAAS LIQKMLQTDP TARPTINELL NDEFFTSGYI PARLPITCLT IPPRFSIAPS SLDPSNRKPL TVLNKGLENP LPERPREKEE PVVRETGEVV DCHLSDMLQQ LHSVNASKPS ERGLVRQEEA EDPACIPIFW VSKWVDYSDK YGLGYQLCDN SVGVLFNDST RLILYNDGDS LQYIERDGTE SYLTVSSHPN SLMKKITLLK YFRNYMSEHL LKAGANITPR EGDELARLPY LRTWFRTRSA IILHLSNGSV QINFFQDHTK LILCPLMAAV TYIDEKRDFR TYRLSLLEEY GCCKELASRL RYARTMVDKL LSSRSASNRL KAS
-
分子量
70 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PLK1 (Polo-like kinase 1) is a pivotal serine/threonine kinase that plays a crucial role in the regulation of cell cycle progression, particularly during mitosis. As a member of the polo-like kinase family, PLK1 is essential for various cellular processes, including centrosome maturation, spindle assembly, and chromosome segregation. Dysregulation of PLK1 has been implicated in several cancers, making it a promising target for therapeutic interventions. The study of recombinant PLK1 protein is vital for understanding its structure-function relationship and regulatory mechanisms in the cell cycle. Recombinant techniques allow researchers to produce PLK1 in sufficient quantities and purity for biochemical assays, structural biology studies, and drug development. By investigating PLK1's interactions with various substrates and inhibitors, scientists can elucidate its role in oncogenesis and identify potential pharmacological agents that selectively inhibit its activity. The ongoing development of PLK1 inhibitors is therefore a significant area of research in cancer therapy, as targeting this kinase could lead to the development of novel treatments that improve patient outcomes. Understanding PLK1 through recombinant protein studies not only enhances our knowledge of cell cycle regulation but also opens avenues for innovative cancer therapies.
